CHANG JOSEPH Y 4
4 · NU SKIN ENTERPRISES, INC. · Filed Mar 3, 2023
Insider Transaction Report
Form 4
CHANG JOSEPH Y
Chief Scientific Officer
Transactions
- Sale
Class A Common Stock
2023-03-02$40.77/sh−25,000$1,019,250→ 21,234 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2023-03-01−26,000→ 600 totalExercise: $30.63Exp: 2023-03-02→ Class A Common Stock (26,000 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2023-03-02−600→ 0 totalExercise: $30.63Exp: 2023-03-02→ Class A Common Stock (600 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2023-03-02−24,400→ 59,410 totalExercise: $30.45Exp: 2027-02-15→ Class A Common Stock (24,400 underlying) - Sale
Class A Common Stock
2023-03-01$40.44/sh−68,485$2,769,533→ 21,234 total - Exercise/Conversion
Class A Common Stock
2023-03-02$30.45/sh+24,400$742,980→ 46,234 total - Exercise/Conversion
Class A Common Stock
2023-03-01$30.63/sh+68,485$2,097,696→ 89,719 total - Exercise/Conversion
Class A Common Stock
2023-03-02$30.63/sh+600$18,378→ 21,834 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2023-03-01−42,485→ 0 totalExercise: $30.63Exp: 2023-03-02→ Class A Common Stock (42,485 underlying)
Holdings
- 78,068(indirect: By Trust)
Class A Common Stock
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.89 to $40.80, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.31 to $41.21, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
- [F3]This report should not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- [F4]Currently exercisable in full.